Prostate Cancer
Oncology·MeSH: Prostatic Neoplasms
Prevalence
256.0 / 100K
Incidence
111.0 / 100K/yr
467 drugs in development·93 companies·191 clinical trials
Drug Pipeline by Phase
Approved(25)
Phase 3(100)
Phase 2(108)
Phase 1(96)
Preclinical(15)
Unknown(10)
Phase 1/Phase 2(54)
Phase 2/Phase 3(1)
| Drug | Company |
|---|---|
| f-dcfpyl | GH Research PLC (GHRS) |
Phase 4(56)
Compare drugs
Frequently asked questions
How many drugs are in development for Prostate Cancer?
BioSniper tracks 467 drugs in development for Prostate Cancer across 93 companies.
How many clinical trials target Prostate Cancer?
There are 191 clinical trials targeting Prostate Cancer tracked by BioSniper.
What is the prevalence of Prostate Cancer?
The estimated prevalence of Prostate Cancer is approximately 256.0 per 100,000 population.
Deep-dive into Prostate Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis